Lisata Therapeutics has formed a strategic partnership with GATC Health to advance AI-driven drug discovery and development.
The collaboration aims to expedite and enhance the success rates of traditional processes involved in drug development.
Go deeper with GlobalData
Lisata will utilise GATC’s Multiomics Advanced Technology (MAT) platform that leverages AI to predict combination therapies that may include Lisata’s certepetide drug candidate.
By applying MAT analysis, any intellectual property generated will be derisked, offering predictions on efficacy, safety and side effects.
Lisata president and CEO David Mazzo stated: “This strategic alliance could be a blueprint for combining the power of advanced AI discovery with deep development expertise to unlock new therapeutic possibilities and bring potentially life-saving treatments to patients faster, more efficiently and at significantly lower cost.
“We see the arrangement between Lisata and GATC as being both strategically and financially symbiotic for our companies.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLisata will bring its expertise in drug development and regulatory affairs to the partnership as the companies progress with the initial development programme for a new therapeutic agent aimed at opioid use disorder (OUD).
Discovered through GATC’s MAT platform, the OUD candidate is a non-opioid small molecule and has shown potential in reducing fentanyl intake during preclinical studies using murine models.
The candidate plans to enter Phase I human trials in early 2026.
GATC’s MAT platform not only identifies potential new drugs but also provides comprehensive analytic reports assessing their likelihood of success or failure within the developmental pipeline.
GATC will cover all research and development costs for its assets while Lisata stands to earn milestone payments along with royalties from net sales upon successful product commercialisation.
Should any assets identified by MAT be acquired by Lisata, GATC is entitled to receive licensing fees on a per-project basis.
